Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
Omeros received $4.02 million in funding from the National Institute on Drug Abuse (NIDA) for clinical development of its OMS527 program to treat cocaine use disorder (CUD).
“Nearly 50 million Americans 12 years of age or older suffered from a substance use disorder in 2022, resulting in estimated societal costs in excess of $1 trillion annually,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. “We look forward to a continued partnership with NIDA to make OMS527 widely available to help CUD and other substance abuse patients and their families.”
Omeros, headquartered in Seattle, continues to solidify the region’s position as a leader in life sciences innovation through its cutting-edge advancements in drug development.